CN102918053A - 用于疫苗的重组蛋白质、针对所述蛋白质的抗体及包括所述蛋白质和抗体的诊断和治疗方法 - Google Patents
用于疫苗的重组蛋白质、针对所述蛋白质的抗体及包括所述蛋白质和抗体的诊断和治疗方法 Download PDFInfo
- Publication number
- CN102918053A CN102918053A CN2011800077474A CN201180007747A CN102918053A CN 102918053 A CN102918053 A CN 102918053A CN 2011800077474 A CN2011800077474 A CN 2011800077474A CN 201180007747 A CN201180007747 A CN 201180007747A CN 102918053 A CN102918053 A CN 102918053A
- Authority
- CN
- China
- Prior art keywords
- protein
- seq
- fragment
- treponema
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 89
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 87
- 229960005486 vaccine Drugs 0.000 title abstract description 22
- 238000002405 diagnostic procedure Methods 0.000 title abstract description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title description 11
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 239000012634 fragment Substances 0.000 claims abstract description 63
- 241000589886 Treponema Species 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 6
- 208000030175 lameness Diseases 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 abstract description 18
- 241000283690 Bos taurus Species 0.000 abstract description 9
- 238000010352 biotechnological method Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 57
- 210000000003 hoof Anatomy 0.000 description 20
- 239000000523 sample Substances 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 15
- 230000004044 response Effects 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 238000013016 damping Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 4
- 208000006413 Digital Dermatitis Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000589970 Spirochaetales Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960003311 ampicillin trihydrate Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000004719 natural immunity Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000589892 Treponema denticola Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000015870 tripotassium citrate Nutrition 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000606006 Dichelobacter Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100023152 Scinderin Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101710204224 Tape measure protein Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000589909 Treponema pallidum subsp. pallidum Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000023867 digital dermatitis in cattle Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- HYXIJVZYRWWFOO-UHFFFAOYSA-N n,n,2,3-tetramethylaniline Chemical compound CN(C)C1=CC=CC(C)=C1C HYXIJVZYRWWFOO-UHFFFAOYSA-N 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108010073419 scinderin Proteins 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29896010P | 2010-01-28 | 2010-01-28 | |
| US61/298,960 | 2010-01-28 | ||
| US36098610P | 2010-07-02 | 2010-07-02 | |
| US61/360,986 | 2010-07-02 | ||
| PCT/SE2011/050090 WO2011093783A1 (en) | 2010-01-28 | 2011-01-28 | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102918053A true CN102918053A (zh) | 2013-02-06 |
Family
ID=44319584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800077474A Pending CN102918053A (zh) | 2010-01-28 | 2011-01-28 | 用于疫苗的重组蛋白质、针对所述蛋白质的抗体及包括所述蛋白质和抗体的诊断和治疗方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8703432B2 (enExample) |
| EP (1) | EP2528939B1 (enExample) |
| JP (1) | JP2013518563A (enExample) |
| CN (1) | CN102918053A (enExample) |
| AU (1) | AU2011209988A1 (enExample) |
| BR (1) | BR112012018840A2 (enExample) |
| CA (1) | CA2825282A1 (enExample) |
| NZ (1) | NZ601980A (enExample) |
| RU (1) | RU2012137304A (enExample) |
| WO (1) | WO2011093783A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10010423B2 (en) | 2013-03-15 | 2018-07-03 | Avinash Kumar | Anatomical humeral fixation system and method |
| DK3017814T3 (en) | 2013-07-03 | 2018-03-12 | Mitsubishi Chemical Foods Corp | PROCEDURE FOR PREVENTION AND / OR TREATMENT OF DIGITAL DERMATITIS |
| US10022458B2 (en) | 2015-03-05 | 2018-07-17 | Iowa State University Research Foundation, Inc. | Animal model protocol, diagnostic, therapeutic and vaccine against digital dermatitis |
| EP3710047A1 (en) * | 2017-11-17 | 2020-09-23 | Hipra Scientific, S.L.U. | Vaccine compositions for use against digital dermatitis in a mammal |
| KR102177180B1 (ko) * | 2020-05-13 | 2020-11-10 | 순천대학교 산학협력단 | 신규 트레포네마 파지데니스 균주 및 이의 분리 방법 |
| KR102177181B1 (ko) * | 2020-05-14 | 2020-11-10 | 순천대학교 산학협력단 | 트레포네마 파지데니스 균주의 배양 조성물 및 이의 용도 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096323A (en) * | 1997-10-03 | 2000-08-01 | The Regents Of The University Of California | Vaccine against papillomatous digital dermatitis (PDD) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0534526A1 (en) * | 1991-09-25 | 1993-03-31 | Duphar International Research B.V | Treponema hyodysenteriae vaccine |
| IL103530A0 (en) * | 1991-10-25 | 1993-03-15 | Duphar Int Res | Treponema hyodysenteriae vaccine |
| US6287575B1 (en) | 1997-10-03 | 2001-09-11 | The Regents Of The University Of California | Vaccine against papillomatous digital dermatitis (PDD) |
-
2011
- 2011-01-28 JP JP2012551129A patent/JP2013518563A/ja active Pending
- 2011-01-28 WO PCT/SE2011/050090 patent/WO2011093783A1/en not_active Ceased
- 2011-01-28 CA CA2825282A patent/CA2825282A1/en not_active Abandoned
- 2011-01-28 AU AU2011209988A patent/AU2011209988A1/en not_active Abandoned
- 2011-01-28 EP EP11737369.6A patent/EP2528939B1/en not_active Not-in-force
- 2011-01-28 US US13/576,032 patent/US8703432B2/en not_active Expired - Fee Related
- 2011-01-28 NZ NZ601980A patent/NZ601980A/en not_active IP Right Cessation
- 2011-01-28 RU RU2012137304/10A patent/RU2012137304A/ru not_active Application Discontinuation
- 2011-01-28 BR BR112012018840A patent/BR112012018840A2/pt not_active IP Right Cessation
- 2011-01-28 CN CN2011800077474A patent/CN102918053A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096323A (en) * | 1997-10-03 | 2000-08-01 | The Regents Of The University Of California | Vaccine against papillomatous digital dermatitis (PDD) |
Non-Patent Citations (3)
| Title |
|---|
| D.J TROTT ET AL: "Characterization of Treponema phagedenis like Spirochetes isolated from papillomatous digital dermatitis lesions in dairy cattle", 《JOURNAL OF CLINICAL MICROBIOLOGY》 * |
| YELTON DB ET AL: "Genbank：M58475.1", 《GENBANK》 * |
| YELTON DB ET AL: "Genbank：P29721.1", 《GENBANK》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2528939A1 (en) | 2012-12-05 |
| JP2013518563A (ja) | 2013-05-23 |
| US20130034560A1 (en) | 2013-02-07 |
| CA2825282A1 (en) | 2011-08-04 |
| US8703432B2 (en) | 2014-04-22 |
| RU2012137304A (ru) | 2014-03-10 |
| WO2011093783A1 (en) | 2011-08-04 |
| NZ601980A (en) | 2014-08-29 |
| EP2528939B1 (en) | 2015-04-08 |
| BR112012018840A2 (pt) | 2017-06-20 |
| EP2528939A4 (en) | 2013-07-03 |
| AU2011209988A1 (en) | 2012-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0807178B1 (fr) | Proteines de mycobacteries, microorganismes les produisant et leurs utilisations vaccinales et pour la detection de la tuberculose | |
| KR102460165B1 (ko) | Ospa의 돌연변이 단편 및 이와 관련된 방법 및 용도 | |
| CN102918053A (zh) | 用于疫苗的重组蛋白质、针对所述蛋白质的抗体及包括所述蛋白质和抗体的诊断和治疗方法 | |
| Olvera et al. | Virulence-associated trimeric autotransporters of Haemophilus parasuis are antigenic proteins expressed in vivo | |
| JP2010535500A (ja) | 免疫原性連鎖球菌タンパク質 | |
| CN110642927A (zh) | 一种蛋白在制备预防化脓隐秘杆菌感染的药物中的应用 | |
| Garibaldi et al. | Immunoprotective activities of a Streptococcus suis pilus subunit in murine models of infection | |
| Bulashev et al. | Immunogenicity and antigenicity of Brucella recombinant outer membrane proteins. | |
| CA2719041C (en) | A method for identifying polypeptides which comprise a cross-reactive antigenic determinant | |
| US10022458B2 (en) | Animal model protocol, diagnostic, therapeutic and vaccine against digital dermatitis | |
| KR20060106809A (ko) | 개과 감염 호흡기 질환에 대해 개에게 백신 접종을 하기위한 백신 조성물 | |
| Rosander et al. | Identification of immunogenic proteins in Treponema phagedenis-like strain V1 from digital dermatitis lesions by phage display | |
| US6162429A (en) | Detection prevention and treatment of Papillomatous Digital Dermatitis | |
| RU2102081C1 (ru) | Иммуногенная композиция против боррелиоза лайма, способ иммунизации млекопитающего против боррелиоза лайма, способ получения белка pc borrelia burgdorferi, диагностический агент для обнаружения b.burgdorferi и способ обнаружения антител к b.burgdorferi | |
| MX2010009516A (es) | Secuencias novedosas de brachyspira, composiciones inmunogenicas, metodos para la preparacion y usos de las mismas. | |
| WO2022180041A1 (en) | Compositions and methods for diagnosing, treating and preventing carrion's disease | |
| CN113754782A (zh) | 一种幽门螺旋杆菌卵黄抗体及其制备方法和应用 | |
| Phoka et al. | Identification of in vivo expressed proteins in live attenuated lipopolysaccharide mutant that mediates heterologous protection against Leptospira spp | |
| Redchuk et al. | Expression of Mycobacterium tuberculosis proteins MPT63 and MPT83 as a fusion: purification, refolding and immunological characterization | |
| US20140248272A1 (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
| Javid | CHARACTERIZATION OF Dichelobacter nodosus AND EXPRESSION OF ITS fimA GENE | |
| Nassrullah et al. | Cloning, Sequencing and Expression of the Brucella Melitensis Novel Lomr Protein. | |
| Venkatesh | Development of recombinant antigens for diagnosis of avian mycoplasmosis | |
| Neto et al. | Diagnostic assays for Rickettsiosis infecti-veness | |
| Hübschle | In memory of Otto Hübschle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20161116 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |